183 related articles for article (PubMed ID: 10917541)
1. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group Workshop--'Clinical endpoints in trials of biological agents'.
Br J Cancer; 2000 Aug; 83(3):294-7. PubMed ID: 10917541
[No Abstract] [Full Text] [Related]
2. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group workshop. Improvements in patient access to new anti-cancer medicines.
Br J Cancer; 1999 Jan; 79(1):2-3. PubMed ID: 10408683
[No Abstract] [Full Text] [Related]
3. The immunoregulatory function of polyphenols: implications in cancer immunity.
de Carvalho JTG; Da Silva Baldivia D; de Castro DTH; Dos Santos HF; Dos Santos CM; Oliveira AS; Alfredo TM; Vilharva KN; de Picoli Souza K; Dos Santos EL
J Nutr Biochem; 2020 Nov; 85():108428. PubMed ID: 32679443
[TBL] [Abstract][Full Text] [Related]
4. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
5. Molecular Targets in Cancer Therapy - Fourth Biennial Meeting. Mechanism and therapeutic reversal of immune suppression in cancer.
Herber DL
IDrugs; 2007 Apr; 10(4):227-9. PubMed ID: 17390239
[No Abstract] [Full Text] [Related]
6. Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
Simon RM; Steinberg SM; Hamilton M; Hildesheim A; Khleif S; Kwak LW; Mackall CL; Schlom J; Topalian SL; Berzofsky JA
J Clin Oncol; 2001 Mar; 19(6):1848-54. PubMed ID: 11251017
[TBL] [Abstract][Full Text] [Related]
7. Ceplene encounters obstacles on the rocky road to FDA approval.
Piascik P
J Am Pharm Assoc (Wash); 2001; 41(2):346-7. PubMed ID: 11297343
[No Abstract] [Full Text] [Related]
8. Immunotherapeutic strategies for neoplasia.
Talmadge JE
Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
[No Abstract] [Full Text] [Related]
9. New wine in old bottles.
Bennett B; Bennett L
Cancer Biother Radiopharm; 2002 Jun; 17(3):249-53. PubMed ID: 12136517
[No Abstract] [Full Text] [Related]
10. The 11th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Cytokines and New Anticancer Agents on the Horizon of Oncology. Nagoya, Japan, 24-25 November 1995.
Cancer Chemother Pharmacol; 1996; 38 Suppl():S1-119. PubMed ID: 8777775
[No Abstract] [Full Text] [Related]
11. Whatever happened to immunotoxins? Research, and hope, are still alive.
Holzman DC
J Natl Cancer Inst; 2009 May; 101(9):624-5. PubMed ID: 19401548
[No Abstract] [Full Text] [Related]
12. [Immunostimulating drugs and cytokines].
Lehners N; Goldschmidt H; Raab MS
Ther Umsch; 2011 Nov; 68(11):655-8. PubMed ID: 22045528
[TBL] [Abstract][Full Text] [Related]
13. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh S; Marabelle A; Soria JC; Armand JP
Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in non-renal carcinomas.
Keilholz U
Urologe A; 2004 Sep; 43 Suppl 3():S138-40. PubMed ID: 15148577
[TBL] [Abstract][Full Text] [Related]
15. [Current status and future perspective of cancer immunotherapy--clinical application and development].
Aruga A
Nihon Geka Gakkai Zasshi; 2013 Nov; 114(6):327-31. PubMed ID: 24358730
[No Abstract] [Full Text] [Related]
16. Biological response modifiers used in cancer biotherapy.
Kuroki M; Miyamoto S; Morisaki T; Yotsumoto F; Shirasu N; Taniguchi Y; Soma G
Anticancer Res; 2012 Jun; 32(6):2229-33. PubMed ID: 22641656
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant application of interferons.
el Kassas H; Kirkwood JM
Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
[No Abstract] [Full Text] [Related]
18. Biological response modifiers: current use and future prospects in cancer therapy.
Bisht M; Bist SS; Dhasmana DC
Indian J Cancer; 2010; 47(4):443-51. PubMed ID: 21131760
[TBL] [Abstract][Full Text] [Related]
19. Innovations in the treatment of melanoma.
Pavlick AC
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-34-7. PubMed ID: 23570097
[No Abstract] [Full Text] [Related]
20. Angiogenesis inhibitors in the treatment of prostate cancer.
Adesunloye BA; Karzai FH; Dahut WL
Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
